Skip to main content
Ind-Swift Laboratories Ltd. logo

Ind-Swift Laboratories Ltd. — Investor Relations & Filings

Ticker · INDSWFTLAB ISIN · INE915B01019 LEI · 335800ZT8UFD9Y8ZMP56 BSE.NS Manufacturing
Filings indexed 809 across all filing types
Latest filing 2024-11-11 Regulatory Filings
Country IN India
Listing BSE.NS INDSWFTLAB

About Ind-Swift Laboratories Ltd.

https://www.indswiftlabs.com

Ind-Swift Laboratories Ltd. is a global manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. The company focuses on research and development, process chemistry, and large-scale production across diverse therapeutic segments, including macrolide antibiotics, cardiovascular agents, antihistamines, antidiabetics, and antipsychotics. Operating multiple manufacturing facilities that adhere to international regulatory standards such as USFDA, EDQM, and PMDA, the organization provides high-quality chemical entities to the global market. Its core competencies lie in complex chemical synthesis and the development of cost-effective manufacturing processes for generic and specialty drug substances. The company maintains a strong emphasis on quality assurance and regulatory compliance to support its extensive portfolio of products distributed worldwide.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2024-11-11 English
Outcome of Board Meeting
Regulatory Filings
2024-11-11 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2024-11-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a Board meeting scheduled to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2024. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The document does not contain the financial results themselves but announces the upcoming board meeting where these results will be approved and taken on record. The document length is short (1890 characters) and it serves as an announcement rather than the actual financial report. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2024-11-06 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2024. It is a compliance certificate issued by the Registrar and Share Transfer Agent confirming the dematerialization of physical share certificates. The document is short (2987 characters) and primarily serves as a certification letter rather than a financial report or detailed filing. It does not contain financial statements or detailed analysis but is a regulatory compliance certificate. According to the Certification Rule, such officer certifications or compliance certificates should be classified as Regulatory Filings (RNS).
2024-10-11 English
Shareholders meeting
Regulatory Filings
2024-10-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.